Research Article

Amelioration of the therapeutic potential of gefitinib against breast cancer using nanostructured lipid carriers

Centre for Advanced Formulation and Technology, Delhi Pharmaceutical Sciences & Research University, New Delhi, 110017, India

Search for more papers by this author

Bharti Mangla

**Author for correspondence:

E-mail Address: bhartipharmacy@gmail.com

https://orcid.org/0000-0001-5125-2150

Centre for Advanced Formulation and Technology, Delhi Pharmaceutical Sciences & Research University, New Delhi, 110017, India

Search for more papers by this author

Shamama Javed

https://orcid.org/0000-0003-2145-9956

Department of Pharmaceutics, College of Pharmacy, Jazan University, P. Box No. 114, Jazan, Saudi Arabia

Search for more papers by this author

Waquar Ahsan

https://orcid.org/0000-0002-5987-2933

Department of Pharmaceutical Chemistry, College of Pharmacy, Jazan University, P. Box No. 114, Jazan, Saudi Arabia

Search for more papers by this author

Geeta Aggarwal

*Author for correspondence:

E-mail Address: prof.geetaaggarwal@gmail.com

https://orcid.org/0000-0002-0568-4267

Centre for Advanced Formulation and Technology, Delhi Pharmaceutical Sciences & Research University, New Delhi, 110017, India

Search for more papers by this author

Published Online:4 Sep 2023https://doi.org/10.2217/nnm-2023-0107

View article

Abstract

Aim: This study aimed to improve the delivery and therapeutic potential of gefitinib (GTB) against breast cancer by preparing GTB-loaded, nanostructured lipid carriers (GTB-NLCs). Materials & methods: Box–Behnken design was used for optimization and GTB was loaded into NLCs using ultrasonication. The GTB-NLCs were characterized using in vitro, ex vivo and in vivo studies. The anticancer efficacy of GTB-NLCs was evaluated using 3-(4,5-dimethythiazol-2-yl)-2,5-diphenyltetrazolium bromide cytotoxicity and flow cytometry on MCF-7 breast cancer cell lines. Results: Optimized GTB-NLCs were successfully characterized and demonstrated improved internalization and enhanced cytotoxicity compared with plain GTB. Gut permeation studies showed enhanced intestinal permeability, and pharmacokinetic analysis revealed 2.6-fold improvement in GTB oral bioavailability. Conclusion: GTB-NLCs effectively enhanced the therapeutic potential of GTB against breast cancer.

Plain language summary

Gefitinib is an important drug approved for the treatment of cancer. However, there are issues with gefitinib, including its low water solubility and toxicity. Being poorly water soluble, the absorption of gefitinib in blood is low and therefore high doses are required to achieve the therapeutic level. Also, gefitinib is nonselective for cancer as well as noncancer cells, leading to toxicity on other organs. This study aimed to incorporate gefitinib into a lipid-based carrier, which improved its properties such as solubility, stability and bioavailability. The prepared formulation was tested for its drug release, stability and efficacy on breast cancer cell lines as well as toxicity using various methods. It was observed that the prepared formulation not only improved bioavailability but also improved the targeting as more gefitinib entered the cancer cells when present in the formulation, decreasing the toxicity of gefitinib on other organs. In conclusion, the prepared formulation can be regarded as an effective approach to improving the therapeutic potential of gefitinib.

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1. Fleege NMG, Cobain EF. Breast cancer management in 2021: a primer for the obstetrics and gynecology. Best Pract. Res. Clin. Obstet. Gynaecol. 82, 30–45 (2022). • Describes the management of breast cancer.
MedlineGoogle Scholar
2. Gupta R, Gupta S, Antonios B et al. Therapeutic landscape of advanced HER2-positive breast cancer in 2022. Med. Oncol. 39(12), 1–14 (2022).
CASGoogle Scholar
3. Gautam N, Elleson KM, Ramamoorthi G, Czerniecki BJ. Current state of cell therapies for breast cancer. Cancer J. 28(4), 301–309 (2002).
Google Scholar
4. Huang L, Jiang S, Shi Y. Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020). J. Hematol. Oncol. 13(1), 1–23 (2020).
MedlineGoogle Scholar
5. Kumar P, Mangla B, Javed S et al. Gefitinib: an updated review of its role in the cancer management, its nanotechnological interventions. Recent Pat. Anticancer Drug Discov. 18(4), 448–469 (2023).
Medline CASGoogle Scholar
6. Wang J, Wang F, Li X et al. Uniform carboxymethyl chitosan-enveloped pluronic F68/poly(lactic-co-glycolic acid) nano-vehicles for facilitated oral delivery of gefitinib, a poorly soluble antitumor compound. Colloids Surf. B. 177, 425–432 (2019).
Medline CASGoogle Scholar
7. Takimoto T, Kijima T, Otani Y et al. Polymorphisms of CYP2D6 gene and gefitinib-induced hepatotoxicity. Clin. Lung Cancer 14(5), 502–507 (2013). •• Describes the toxicity of gefitinib.
Medline CASGoogle Scholar
8. Alhoshani A, Alanazi FE, Alotaibi MR et al. EGFR inhibitor gefitinib induces cardiotoxicity through the modulation of cardiac PTEN/Akt/FOXO3a pathway and reactive metabolites formation: in vivo and in vitro rat studies. Chem. Res. Toxicol. 33(7), 1719–1728 (2020).
Medline CASGoogle Scholar
9. You KS, Yi YW, Cho J, Seong YS. Dual inhibition of AKT and MEK pathways potentiates the anti-cancer effect of GTB in triple-negative breast cancer cells. Cancers 13(6), 1205 (2021).
Medline CASGoogle Scholar
10. Fang S, Zhong J, Mai Z et al. Efficacy of adjuvant chemotherapy on overall survival in patients with lymph node-positive esophageal squamous cell carcinoma: is oral chemotherapy promising? Cancer Med. 12(4), 4077–4086 (2023).
Medline CASGoogle Scholar
11. Kumar P, Mangla B, Javed S et al. A review of nanomaterials from synthetic and natural molecules for prospective breast cancer nanotherapy. Front. Pharmacol. 14, 117 (2023). •• Describes nanoparticles for breast cancer treatment.
Google Scholar
12. Mirza Z, Karim S. Nanoparticles-based drug delivery and gene therapy for breast cancer: recent advancements and future challenges. Semin. Cancer Biol. 69, 226–237 (2021).
Medline CASGoogle Scholar
13. Pindiprolu SKSS, Krishnamurthy PT, Krishnamurthy PK et al. Recent advances in lipid-based nanoformulations for breast cancer theranostics. Cancer Nanotheran. 2, 175–200 (2021).
Google Scholar
14. Amin H, Osman SK, Mohammad AM, Zayed G. Gefitinib-loaded starch nanoparticles for battling lung cancer: optimization by full factorial design and in vitro cytotoxicity evaluation. Saudi Pharm. J. 31(1), 29–54 (2023).
Medline CASGoogle Scholar
15. Nayek S, Raghavendra NM, Sanjeev Kumar B. Development of novel S PC-3 gefitinib lipid nanoparticles for effective drug delivery in breast cancer. Tissue distribution studies and cell cytotoxicity analysis. J. Drug Deliv. Sci. Technol. 61, 102073 (2021).
CASGoogle Scholar
16. Gupta M, Marwaha RK, Dureja H. Development and characterization of gefitinib loaded polymeric nanoparticles by ionic gelation method. Pharm. Nanotechnol. 5(4), 301–309 (2017). • Describes gefitinib-loaded nanoformulations.
Medline CASGoogle Scholar
17. Zhou Z, Yung B, Huang Y et al. Novel liposomal gefitinib (L-GEF) formulations. Anticancer Res. 32(7), 2919–2923 (2012).
Medline CASGoogle Scholar
18. Guada M, Lana H, Gil AG, del Carmen Dios-Viéitez M, Blanco-Prieto MJ. Cyclosporine A lipid nanoparticles for oral administration: pharmacodynamics and safety evaluation. Eur. J. Pharm. Biopharm. 101, 112–118 (2016).
Medline CASGoogle Scholar
19. Khairnar SV, Pagare P, Thkare A et al. Review on the scale-up methods for the preparation of solid lipid nanoparticles. Pharmaceutics 14(9), 1886 (2022).
Medline CASGoogle Scholar
20. Javed S, Mangla B, Almoshari Y, Sultan MH, Ahsan W. Nanostructured lipid carrier system: a compendium of their formulation development approaches, optimization strategies by quality by design, and recent applications in drug delivery. Nanotechnol. Rev. 11(1), 1744–1777 (2022).
CASGoogle Scholar
21. Singh A, Neupane YR, Mangla B, Kohli K. Nanostructured lipid carriers for oral bioavailability enhancement of exemestane: formulation design, in vitro, ex vivo, and in vivo studies. J. Pharm. Sci. 108(10), 3382–3395 (2019).
Medline CASGoogle Scholar
22. Ranpise NS, Korabu SS, Ghodake VN. Second generation lipid nanoparticles (NLC) as an oral drug carrier for delivery of lercanidipine hydrochloride. Colloids Surf. B. 116, 81–87 (2014).
Medline CASGoogle Scholar
23. Kumar P, Mangla B, Beg S et al. Optimization and validation of stability indicating RP-HPLC method for the quantification of gefitinib in bulk drug and nanoformulations: an application towards in vitro and ex vivo performance evaluation. Arab. J. Chem. 15(12), 104333 (2022).
CASGoogle Scholar
24. Mangla B, Neupane YR, Sign A et al. Lipid-nanopotentiated combinatorial delivery of tamoxifen and sulforaphane: ex vivo, in vivo and toxicity studies. Nanomedicine 15(26), 2563–2583 (2020). •• Describes the preparation of lipid-based nanoformulations.
CASGoogle Scholar
25. Lakhani P, Patil A, Taskar P, Ashour E, Majumdar S. Curcumin-loaded nanostructured lipid carriers for ocular drug delivery: design optimization and characterization. J. Drug Deliv. Sci. Technol. 47, 159–166 (2018).
Medline CASGoogle Scholar
26. Sartaj A, Annu, Biswas L et al. Ribociclib nanostructured lipid carrier aimed for breast cancer: formulation optimization, attenuating in vitro specification, and in vivo scrutinization. Biomed. Res. Int. 2022, 24 (2022).
Google Scholar
27. Chitkara A, Mangla B, Kumar P et al. Design-of-experiments (DoE)-assisted fabrication of quercetin-loaded nanoemulgel and its evaluation against human skin cancer cell lines. Pharmaceutics 14(11), 2517 (2022). •• Describes the nanoparticles optimized by design of experiment.
Medline CASGoogle Scholar
28. Mohit, Kumar P, Solanki P, Mangla B, Aggarwal G. Formulation development, optimization by Box–Behnken design, and in vitro characterization of gefitinib phospholipid complex based nanoemulsion drug delivery system. J. Pharm. Innov. 14, 1–13 (2022).
Google Scholar
29. Ye Q, Li J, Li T et al. Development and evaluation of puerarin-loaded controlled release nanostructured lipid carries by central composite design. Drug Dev. Ind. Pharm. 47(1), 113–125 (2021).
Medline CASGoogle Scholar
30. Cernam T, Dinesh S, Narendar D, Nagaraj B. Enhanced pharmacokinetic activity of zotepine via nanostructured lipid carrier system in Wistar rats for oral application. Pharm. Nanotechnol. 8(2), 148–160 (2020).
MedlineGoogle Scholar
31. Sharma T, Katare OP, Jain A et al. QbD-steered development of biotin-conjugated nanostructured lipid carriers for oral delivery of chrysin: role of surface modification for improving biopharmaceutical performance. Colloids Surf. B. 197, 111429 (2021).
Medline CASGoogle Scholar
32. Singh A, Neupane YR, Shafi S, Mangla B, Kohli K. PEGylated liposomes as an emerging therapeutic platform for oral nanomedicine in cancer therapy: in vitro and in vivo assessment. J. Mol. Liq. 303, 112649 (2020).
CASGoogle Scholar
33. Jazuli I, Annu, Nabbi B et al. Optimization of nanostructured lipid carriers of lurasidone hydrochloride using Box–Behnken design for brain targeting: in vitro and in vivo studies. J. Pharm. Sci. 108(9), 3082–3090 (2019).
Medline CASGoogle Scholar
34. Agrawal M, Saraf S, Pradhan M et al. Design and optimization of curcumin loaded nano lipid carrier system using Box–Behnken design. Biomed. Pharmacother. 141, 111919 (2021).
Medline CASGoogle Scholar
35. Thapa C, Ahad A, Aqil M, Imam SS, Sultana Y. Formulation and optimization of nanostructured lipid carriers to enhance oral bioavailability of telmisartan using Box–Behnken design. J. Drug Deliv. Sci. Technol. 44, 431–439 (2018). • Describes the use of solid and liquid lipid in the preparation of nanostructured, lipid-based carriers.
CASGoogle Scholar
36. Demirbolat GM, Coskun GP, Erdogan O, Cevik O. Long chain fatty acids can form aggregates and affect the membrane integrity. Colloids Surf. B. 204, 111795 (2021).
Medline CASGoogle Scholar
37. Patti A, Lecocq H, Sergehi A, Acierno D, Cassagnau P. The universal usefulness of stearic acid as surface modifier: applications to the polymer formulations and composite processing. J. Ind. Eng. Chem. 96, 1–33 (2021).
CASGoogle Scholar
38. Abbott S. Solubility, similarity, and compatibility: a general-purpose theory for the formulator. Curr. Opin. Colloid Interface Sci. 48, 65–76 (2020).
CASGoogle Scholar
39. Makeen HA, Mohan S, Al-Kasim MA et al. Gefitinib loaded nanostructured lipid carriers: characterization, evaluation and anti-human colon cancer activity in vitro. Drug Deliv. 27(1), 622–631 (2020).
Medline CASGoogle Scholar
40. Sherif AY, Harisa GI, Shahba AA, Alanazi FK, Qamar W. Optimization of gefitinib-loaded nanostructured lipid carrier as a biomedical tool in the treatment of metastatic lung cancer. Molecules 28(1), 448 (2023).
Medline CASGoogle Scholar
41. Muller RH, Runge SA, Ravelli A et al. Cyclosporine-loaded solid lipid nanoparticles (SLN^®): drug–lipid physicochemical interactions and characterization of drug incorporation. Eur. J. Pharm. Biopharm. 68(3), 535–544 (2008).
Medline CASGoogle Scholar
42. Poonia N, Narang JK, Lather V et al. Resveratrol loaded functionalized nanostructured lipid carriers for breast cancer targeting: systematic development, characterization and pharmacokinetic evaluation. Colloids Surf. B. 181, 756–766 (2019). • Discusses the mechanism of lipid-based formulations.
Medline CASGoogle Scholar
43. Rennick RJ, Johnston APR, Parton RG. Key principles and methods for studying the endocytosis of biological and nanoparticle therapeutics. Nat. Nanotechnol. 16(3), 266–276 (2021).
Medline CASGoogle Scholar
44. Tamjidi F, Tamjidi M, Varshosaz J, Nasirpour A. A potential delivery system for bioactive food molecules. Innov. Food Sci. Emerg. Technol. 19, 29–43 (2013).
CASGoogle Scholar
45. Makoni PA, Kasongo KW, Walker RB. Short term stability testing of efavirenz-loaded solid lipid nanoparticle (SLN) and nanostructured lipid carrier (NLC) dispersions. Pharmaceutics 11(8), 397 (2019).
Medline CASGoogle Scholar
46. Madane RG, Mahajan HS. Curcumin-loaded nanostructured lipid carriers (NLCs) for nasal administration: design, characterization, and in vivo study. Drug Deliv. 23(4), 1326–1334 (2016).
Medline CASGoogle Scholar
47. Jain NK, Ram A. Development and characterization of nanostructured lipid carriers of oral hypoglycemic agent: selection of surfactants. Int. J. Pharm. Sci. Rev. Res. 7(2), 125–130 (2011).
CASGoogle Scholar
48. Elmowafy M, Al-Sanea MM. Nanostructured lipid carriers (NLCs) as drug delivery platform: advances in formulation and delivery strategies. Saudi Pharm. J. 29(9), 999–1012 (2021).
Medline CASGoogle Scholar
49. Abdelhakeem E, El-Nabarawi M, Shamma R. Lipid-based nano-formulation platform for eplerenone oral delivery as a potential treatment of chronic central serous chorioretinopathy: in-vitro optimization and ex-vivo assessment. Drug Deliv. 28(1), 642–654 (2021).
Medline CASGoogle Scholar
50. Mahmood A, Rapalli VK, Gorantla S, Waghule T, Singhvi G. Dermatokinetic assessment of luliconazole-loaded nanostructured lipid carriers (NLCs) for topical delivery: qbD-driven design, optimization, and in vitro and ex vivo evaluations. Drug Deliv. Transl. Res. 12(5), 1118–1135 (2022).
Medline CASGoogle Scholar
51. Tran TH, Ramasamy T, Truong DH et al. Preparation and characterization of fenofibrate-loaded nanostructured lipid carriers for oral bioavailability enhancement. AAPS Pharm. Sci. Tech. 15, 1509–1515 (2014).
Medline CASGoogle Scholar
52. Luan J, Zheng F, Yang X, Yu A, Zhai G. Nanostructured lipid carriers for oral delivery of baicalin: in vitro and in vivo evaluation. Colloids Surf. 466, 154–159 (2015).
CASGoogle Scholar
53. Gadhe AP, Kyadarkunte A, Patole A, Pokharkar V. Montelukast-loaded nanostructured lipid carriers: part II pulmonary drug delivery and in vitro–in vivo aerosol performance. Eur. J. Pharm. Biopharm. 88(1), 169–177 (2014). •• Applications of nanostructured, lipid-based carriers and other lipid-based formulations.
MedlineGoogle Scholar
54. Ahalawat S, Bhatt DC. Development of novel lipid matrix for improved sustained release effect of a hydrophilic drug via response surface methodology. J. Drug Deliv. Sci. Technol. 67, 102993 (2022).
Google Scholar
55. Nguyen VH, Thuy VN, Van TV, Dao AH, Lee BJ. Nanostructured lipid carriers and their potential applications for versatile drug delivery via oral administration. Open Nano 8, 100064 (2022).
Google Scholar
56. Piazzini V, Leemi B, D'Ambrosio A et al. Nanostructured lipid carriers as promising delivery systems for plant extracts: the case of silymarin. Appl. Sci. 8(7), 1163 (2018).
Google Scholar
57. Rohilla S, Awasthi R, Mehta M et al. Preparation and evaluation of gefitinib containing nanoliposomal formulation for lung cancer therapy. BioNanoScience 12(1), 241–255 (2022).
Google Scholar
58. Cortes H, Parra HH, Bernal-Chavez SA et al. Non-ionic surfactants for stabilization of polymeric nanoparticles for biomedical uses. Materials 14(12), 3197 (2021).
Medline CASGoogle Scholar
59. Ramachandran C, Khatib Z, Pefkarou A et al. Tamoxifen modulation of etoposide cytotoxicity involves inhibition of protein kinase C activity and insulin-like growth factor II expression in brain tumor cells. J. Neurooncol. 67, 19–28 (2014).
Google Scholar
60. Elsheikh MA, Elnaggar YSR, Hamdy AD, Abdallah YO. Novel cremochylomicrons for improved oral bioavailability of the antineoplastic phytomedicine berberine chloride: optimization and pharmacokinetics. Int. J. Pharm. 535(1–2), 316–324 (2018).
Medline CASGoogle Scholar
61. Maher S, Brayden DJ. Formulation strategies to improve the efficacy of intestinal permeation enhancers. Adv. Drug Deliv. Rev. 177, 113925 (2021). •• Formulation strategies of nanostructured, lipid-based carriers.
Medline CASGoogle Scholar
62. Danielsen EM. Intestinal permeation enhancers: lessons learned from studies using an organ culture model. Biochim. Biophys. Acta Biomembr. 1863(1), 183474 (2021).
Medline CASGoogle Scholar
63. Khosa A, Reddi S, Saha RN. Nanostructured lipid carriers for site-specific drug delivery. Biomed. Pharmacother. 103, 598–613 (2018).
Medline CASGoogle Scholar
64. Sherif AY, Harisa GI, Alanazi FK, Nasr FA, Alqahtani AS. Engineered nanoscale lipid-based formulation as potential enhancer of gefitinib lymphatic delivery: cytotoxicity and apoptotic studies against the A549 cell line. AAPS PharmSciTech. 23(6), 183 (2022).
Medline CASGoogle Scholar
65. Sherif AY, Harisa GI, Alanazi FK, Nasr FA, Alqahtani AS. PEGylated SLN as a promising approach for lymphatic delivery of gefitinib to lung cancer. Int. J. Nanomed. 28, 3287–3311 (2022).
Google Scholar
66. Agrawal YO, Patil KD, More KR et al. Amelioration of bioavailability through formulating and optimizing azilsartan entrapped nanostructured lipid carriers and its pharmacokinetic assessment. J. Drug Deliv. Sci. Technol. 77, 103894 (2022).
CASGoogle Scholar
67. Jawahar N, Hingarh PK, Arun R et al. Enhanced oral bioavailability of an antipsychotic drug through nanostructured lipid carriers. Int. J. Biol. Macromol. 110, 269–275 (2018).
Medline CASGoogle Scholar
68. Azar FAN, Pezeshki A, Ghanbarzadeh B, Hamishehkar H, Mohammadi M. Nanostructured lipid carriers: promising delivery systems for encapsulation of food ingredients. J. Agric. Res. 2, 100084 (2020).
Google Scholar
69. Das S, Ng WK, Tan RBH. Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs): development, characterizations and comparative evaluations of clotrimazole-loaded SLNs and NLCs? Eur. J. Pharm. Sci. 47(1), 139–151 (2012). •• Applications of nanostructured, lipid-based carriers.
Medline CASGoogle Scholar
70. Beloqui A, Pozo-Rodríguez AD, Isla A, Rodríguez-Gascón A, Solinís MA. Nanostructured lipid carriers as oral delivery systems for poorly soluble drugs. J. Drug Deliv. Sci. Technol. 42, 144–154 (2017).
CASGoogle Scholar
71. Severino P, Andreani T, Macedo AS et al. Current state-of-art and new trends on lipid nanoparticles (SLN and NLC) for oral drug delivery. J. Drug Deliv. 2012, 750891 (2012).
MedlineGoogle Scholar

Vol. 18, No. 18

Supplemental Materials

Metrics

Downloaded 44 times

History

Received 8 April 2023

Accepted 3 August 2023

Published online 4 September 2023

Published in print August 2023

Information

Keywords

Supplementary data

To view the supplementary data that accompany this paper please visit the journal website at: www.futuremedicine.com/doi/suppl/10.2217/nnm-2023-0107

Financial & competing interests disclosure

The authors report no conflicts of interest. The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending or royalties.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all animal experimental investigations. All rats were approved through Committee for the Purpose of Control and Supervision of Experiments on Animals guidelines by the Institutional Ethics Committee at Delhi Pharmaceutical Sciences and Research University (DPSRU), New Delhi, India, with protocol no. IEAC/2022/I-R05.

PDF download